We have now performed a multi-institutional study to investigate the prevalence of T790M in patients with EGFR mutation–positive NSCLC at the time of disease progression during treatment with afatinib as first-line EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.